On the other hand, PPARA is a transcriptional modulator of fatty acid transport, peroxisomal and mitochondrial FAO pathways [56] and, thus, through its pro-oxidative anti-lipotoxic effects, their ligands are successfully used to treat primary and secondary forms of hypertriglyceridemia, particularly associated with MetS [57]. Here, PPARA is linked to hypertriglyceridemia.